UBS Maintains Neutral on Quest Diagnostics, Raises Price Target to $146
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Kevin Caliendo maintains a Neutral rating on Quest Diagnostics (NYSE:DGX) and raises the price target from $139 to $146.

April 24, 2024 | 3:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS analyst Kevin Caliendo maintains a Neutral rating on Quest Diagnostics and raises the price target from $139 to $146.
The increase in price target by UBS suggests a positive outlook on the stock's value, potentially leading to increased investor interest and a short-term positive impact on the stock price. However, the maintenance of a Neutral rating indicates that the analyst sees the stock as fairly valued at its current price, balancing the potential for significant short-term price movement.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100